Yale, Biohaven Win $4M In Biotech Trade Secret Trial
law360
5 hours ago
0 views
A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million after finding that venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with co-defendant Avilar Therapeutics, misappropriated a Yale-developed trade secret for designing protein-degrading drug molecules.
Continue Reading
Sign up for FREE to read the full article and access 136K+ alternative investment headlines.